NIPRIDE RTU IN SODIUM CHLORIDE 0.9%
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Sodium nitroprusside is a potent vasodilator that acts by releasing nitric oxide (NO), which activates guanylyl cyclase in vascular smooth muscle cells, increasing cGMP levels and leading to relaxation of both arterial and venous smooth muscle, thereby reducing peripheral resistance and cardiac preload.
| Metabolism | Sodium nitroprusside is rapidly metabolized by non-enzymatic reaction with sulfhydryl groups in erythrocytes and tissues to release cyanide. Cyanide is further metabolized to thiocyanate by the mitochondrial enzyme rhodanese in the liver and kidneys. Thiocyanate is renally eliminated. |
| Excretion | Renal: 40-60% as thiocyanate at therapeutic doses; biliary: minimal; fecal: negligible. |
| Half-life | Nitroprusside: ~2 minutes (converted to cyanide); cyanide: 1-2 hours (converted to thiocyanate); thiocyanate: 2.7-7 days (up to 14 days in renal impairment). Clinical context: Thiocyanate accumulation risk with prolonged use. |
| Protein binding | Nitroprusside: negligible; cyanide: 60% (to albumin and other proteins); thiocyanate: 20-40% (primarily albumin). |
| Volume of Distribution | Nitroprusside: 0.2 L/kg; cyanide: 0.3-0.5 L/kg; thiocyanate: 0.2-0.3 L/kg. Clinical meaning: Small Vd indicates limited tissue distribution. |
| Bioavailability | IV: 100% (only route); oral: 0% (not absorbed due to instability and first-pass metabolism). |
| Onset of Action | IV: 30-60 seconds; immediate hypotensive effect. |
| Duration of Action | IV: 1-10 minutes after stopping infusion; rapid offset due to short half-life. |
| Molecular Weight | 261.97 |
Initial 0.3-0.5 mcg/kg/min IV continuous infusion, titrate by 0.5 mcg/kg/min every 3-5 minutes to desired effect; usual range 3-6 mcg/kg/min; maximum 10 mcg/kg/min.
| Dosage form | SOLUTION |
| Renal impairment | Contraindicated in severe renal failure (eGFR <30 mL/min) due to risk of thiocyanate toxicity. For eGFR 30-60 mL/min, reduce dose by 50% and monitor thiocyanate levels. No adjustment for eGFR >60 mL/min. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). For Child-Pugh class A or B, use with caution; reduce infusion rate by 50% and monitor cyanide levels due to impaired metabolism. |
| Pediatric use | Children: Initial 0.3-0.5 mcg/kg/min IV infusion; titrate by 0.5-1 mcg/kg/min every 5 minutes to effect; usual dose 1-4 mcg/kg/min; maximum 10 mcg/kg/min. Neonates: Not recommended due to limited data and risk of cyanide toxicity. |
| Geriatric use | Elderly: Start at lower end of dosing range (0.25-0.3 mcg/kg/min) due to increased sensitivity and potential renal impairment. Titrate cautiously. Monitor for hypotension and thiocyanate accumulation. |
| 1st trimester | Contraindicated due to risk of fetal cyanide toxicity and potential teratogenic effects from nitroprusside metabolites. |
| 2nd trimester | Use only if clearly needed; may cause fetal cyanide accumulation with prolonged infusion. Limited data. |
| 3rd trimester | Avoid near term; can cause fetal bradycardia, hypotension, and cyanide toxicity. May lead to uterine relaxation and prolonged labor. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Crosses placenta rapidly; fetal cyanide levels may approach maternal levels with prolonged infusion. |
| Breastfeeding | Sodium nitroprusside has very short half-life and is rapidly metabolized; significant excretion into breast milk is unlikely. However, caution is advised as cyanide metabolites may accumulate in infants with prolonged exposure. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | Sodium nitroprusside is a pregnancy category C drug. Animal studies have shown embryotoxicity and teratogenicity (skeletal anomalies) at doses exceeding human therapeutic levels. Fetal risks include cyanide toxicity, hypotension, and metabolic acidosis from maternal infusion, especially in third trimester. Use only if benefit outweighs risk, with caution to avoid maternal hypotension. |
| Fetal Monitoring | Continuous arterial blood pressure monitoring via intra-arterial catheter; heart rate; IV site observation; serum cyanide and thiocyanate levels (if infusion >2 mcg/kg/min or duration >24 hours); acid-base status (metabolic acidosis may indicate cyanide toxicity); fetal heart rate monitoring if maternal hypotension occurs. |
| Fertility Effects | No data available on effects of sodium nitroprusside on human fertility. Animal studies have not been conducted specifically for fertility endpoints. |
■ FDA Black Box Warning
Sodium nitroprusside can cause excessive hypotension, leading to irreversible cerebral ischemia, myocardial infarction, or death. Also, it can cause cyanide toxicity, especially with prolonged infusion, high doses, or in patients with hepatic impairment. Continuous monitoring of blood pressure and cyanide levels is required.
| Common Effects | fluid replacement |
| Serious Effects |
Compensatory hypertension (e.g., aortic coarctation, arteriovenous shunt)Leber's hereditary optic atrophyTobacco amblyopiaSevere hepatic insufficiencySevere renal impairmentKnown hypersensitivity to sodium nitroprussideCongenital optic atrophy
| Precautions | Monitor blood pressure closely to avoid severe hypotension, Assess for cyanide toxicity, especially in patients with hepatic or renal impairment, Monitor for thiocyanate toxicity, particularly with renal impairment, Use with caution in patients with hypovolemia, severe anemia, or increased intracranial pressure, Avoid prolonged use (beyond 72 hours) due to risk of cyanide accumulation |
| Food/Dietary | No significant food interactions. However, patients with hypertensive emergencies may be on a sodium-restricted diet; note that this product is formulated in 0.9% sodium chloride. |
| Clinical Pearls | Nipride RTU (sodium nitroprusside) is a potent, rapid-onset vasodilator used for hypertensive emergencies. Due to light sensitivity, the infusion must be protected from light using an opaque wrapping. Cyanide toxicity is a risk with prolonged use or high doses; monitor for metabolic acidosis and elevated lactate. Avoid in patients with renal impairment due to thiocyanate accumulation. Use with caution in patients with hepatic insufficiency as cyanide clearance may be reduced. Discontinue if cyanide toxicity is suspected and consider antidote therapy (e.g., sodium thiosulfate). |
| Patient Advice | This medication is given intravenously to rapidly lower severely high blood pressure. · You will be in a closely monitored setting, such as an intensive care unit. · Tell your healthcare provider immediately if you experience headache, dizziness, nausea, confusion, or difficulty breathing. · The infusion bag will be covered to protect the medication from light; do not remove the cover. · Avoid sudden movements or getting up quickly to prevent dizziness from low blood pressure. |
Loading safety data…